Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly, Schrödinger Enter Drug Design Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lilly, Schrödinger Enter Drug Design Collaboration

Schrödinger will receive as much as $425 million in discovery, development and commercial milestones for the optimization of small molecule compounds.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Schrödinger, a computational technology has entered a drug design collaboration with Eli Lilly.
 
Schrödinger will receive as much as $425 million in discovery, development and commercial milestone payments and will be responsible for the discovery and optimization of small molecule compounds addressing an undisclosed target.

Once complete, Lilly will then be responsible for the completion of preclinical development, clinical development and commercialization. Lilly will participate in the early stages of development, including working with animal models to help characterize compounds. Schrödinger will also be eligible to receive royalties on any asset that becomes commercialized.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics